The review article “Current Perspectives on Benefits and Risks of Hormone Replacement Therapy” (2001) examines the effects of hormone replacement therapy (HRT) on postmenopausal women’s health, highlighting potential benefits and risks. Findings suggest that HRT users experience a 34% reduction in colorectal cancer risk and a 20% to 60% reduction
The study titled “Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells” (Maturitas, 2007, PMID: 16962266) investigates how different progestogens impact estrogen metabolism in human breast cancer cells. Findings suggest that various progestogens, depending on type and regimen, differentially regulate estrogen-metabolizing enzymes, potentially
A study published in the Journal of the National Cancer Institute in 2000 (PMID: 10675382) examined the effects of hormone replacement therapy (HRT) on breast cancer risk among postmenopausal women aged 55-72. The analysis of 1,897 breast cancer cases and 1,637 controls found that combined HRT (estrogen plus progestin) increased
This systematic review evaluates the use of testosterone therapy for improving sexual desire in women and weighs it against the risk of breast cancer. The review suggests that testosterone may offer modest improvements in sexual desire but poses a significant risk for breast cancer. Due to limited long-term studies and
This article reviews the use of testosterone supplementation for libido enhancement in postmenopausal women, noting that while it provides benefits, there are concerns about its potential to increase breast cancer risk due to the conversion of testosterone into oestradiol. The article calls for more high-quality studies to assess long-term safety.
This meta-analysis of 51 epidemiological studies involving 52,705 women with breast cancer and 108,411 without examined the link between hormone replacement therapy (HRT) and breast cancer risk. The findings showed that current HRT use increases breast cancer risk, with the risk rising with prolonged use but diminishing after cessation. The
This cohort study from the Million Women Study found that current hormone replacement therapy (HRT) use is linked to an increased risk of both incident and fatal breast cancer, with the risk being particularly higher for estrogen-progestagen combinations. The risk rises with the duration of use but decreases after cessation
This observational study from the E3N-EPIC cohort investigated the relationship between various hormone replacement therapy (HRT) regimens and breast cancer risk. The study found that combining estrogens with synthetic progestins increased breast cancer risk, even for short durations, while transdermal estrogens with synthetic progestins also showed an elevated risk. However,
This review article discusses the potential impact of combining testosterone with estrogen in hormone replacement therapy for postmenopausal women and its associated risks, including breast cancer. It emphasizes the need for careful evaluation when using testosterone therapy alongside estrogen, especially for women with low sexual desire disorder, highlighting the importance
This article reviews the relationship between postmenopausal hormone therapy and breast cancer risk. It finds that estrogen alone may slightly reduce breast cancer risk, while combined estrogen-progestin therapy significantly increases it. Notably, current estrogen-progestin use is linked to a higher risk of lobular cancer than ductal cancer, although the risk
